HeartSciences Inc. has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance. The device is designed to offer conventional ECG functionality and serve as a platform for AI-ECG algorithms. The FDA submission marks a significant regulatory milestone for the company as it continues its commercialization efforts. The company has chosen to submit the device and its associated AI-ECG software algorithm separately to simplify the regulatory process and accelerate device clearance. No grant or funding involving HeartSciences Inc. is mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601967-en) on December 15, 2025, and is solely responsible for the information contained therein.